Visa suspends Morgan Freeman campaign after accusations of inappropriate behavior

Visa is suspending its marketing campaign with Morgan Freeman following a CNN investigation that uncovered a pattern of alleged harassment and inappropriate behavior by the actor.

"We are aware of the allegations that have been made against Mr. Freeman. At this point, Visa will be suspending our marketing in which the actor is featured," the company said late Thursday.

The company has featured Freeman in its commercials and also used his voice in its ads.

Vancouver public transit system TransLink announced on Thursday that it would "pause" its current ad campaign, which features Freeman's voice promoting its Visa credit card and mobile payments on the transit system.

"In light of information we learned Thursday morning of allegations regarding actor Morgan Freeman, TransLink has decided to pause his voice announcements as part of a Visa ad campaign on our transit system. We will be reaching out to Visa to discuss further," a spokesperson said.

In all, 16 people spoke to CNN about Freeman as part of an investigation, eight of whom said they were victims of what some called harassment and others called inappropriate behavior by Freeman. Eight said they witnessed Freeman's alleged conduct. These 16 people together described a pattern of inappropriate behavior by Freeman on set, while promoting his movies and at his production company Revelations Entertainment.

The Screen Actors Guild also said it is in the process of determining what, if any, action will be necessary regarding Freeman, who received its lifetime achievement award in January.

"These are compelling and devastating allegations which are absolutely contrary to all the steps that we are taking to insure (sic) a safe work environment for the professionals in this industry," the union said in a statement via a SAG-AFTRA spokesperson. "Any accused person has the right to due process, but it is our starting point to believe the courageous voices who come forward to report incidents of harassment. Given Mr. Freeman recently received one of our union's most prestigious honors recognizing his body of work, we are therefore reviewing what corrective actions may be warranted at this time."

Morgan Freeman's spokesman did not immediately respond to a request for comment about his work with Visa and Vancouver's TransLink, or his SAG award.

Freeman, 80, issued a statement after the allegations surfaced, saying he is "not someone who would intentionally offend or knowingly make anyone feel uneasy. I apologize to anyone who felt uncomfortable or disrespected �� that was never my intent."

Best Biotech Stocks To Watch For 2018

tags:ALNY,ARQL,BIIB,AMGN,

Atara Biotherapeutics (NASDAQ:ATRA) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.13), MarketWatch Earnings reports.

Atara Biotherapeutics traded up $0.10, hitting $39.70, during trading hours on Thursday, Marketbeat reports. The company’s stock had a trading volume of 345,041 shares, compared to its average volume of 490,755. The firm has a market capitalization of $1.74 billion, a PE ratio of -9.93 and a beta of 2.55. Atara Biotherapeutics has a 52-week low of $39.60 and a 52-week high of $41.55.

Get Atara Biotherapeutics alerts:

In other Atara Biotherapeutics news, CFO John Mcgrath sold 13,000 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $47.07, for a total value of $611,910.00. Following the completion of the transaction, the chief financial officer now owns 99,056 shares in the company, valued at $4,662,565.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Isaac E. Ciechanover sold 8,800 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $37.44, for a total transaction of $329,472.00. Following the completion of the transaction, the chief executive officer now owns 808,675 shares of the company’s stock, valued at approximately $30,276,792. The disclosure for this sale can be found here. Insiders sold 186,168 shares of company stock worth $7,952,433 in the last three months. 10.60% of the stock is currently owned by corporate insiders.

Best Biotech Stocks To Watch For 2018: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors' Opinion:

• [By Max Byerly]

  Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.

• [By Brian Orelli]

  The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn't think a few months will really matter: "We don't really feel that's going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we're very well prepared to be ready to launch following approval."

• [By Keith Speights]

  I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick -- but with a couple of qualifications. First, I didn't think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.

Best Biotech Stocks To Watch For 2018: ArQule Inc.(ARQL)

Advisors' Opinion:

• [By Lisa Levin] Gainers Foot Locker, Inc. (NYSE: FL) rose 15.3 percent to $53.50 in pre-market trading after the company reported better-than-expected results for its first quarter. Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 10.4 percent to $4.58 in pre-market trading. Evofem Biosciences reported closing of public offering of common stock and warrants. Resonant Inc. (NASDAQ: RESN) rose 7.3 percent to $4.88 in pre-market trading after declining 1.94 percent on Thursday. SolarEdge Technologies, Inc. (NASDAQ: SEDG) shares rose 5.7 percent to $59.65 in pre-market trading after falling 8.43 percent on Thursday. Yirendai Ltd. (NYSE: YRD) rose 5 percent to $30.00 in pre-market trading after reporting Q1 results. Deckers Outdoor Corp (NYSE: DECK) rose 4.9 percent to $108.75 in pre-market trading after reporteingd better-than-expected results for its fiscal fourth quarter. Blue Apron Holdings, Inc. (NYSE: APRN) rose 4.2 percent to $3.21 in pre-market trading after gaining 3.70 percent on Thursday. Recro Pharma, Inc. (NASDAQ: REPH) rose 4 percent to $5.85 in pre-market trading after dropping 54.67 percent on Thursday. ArQule, Inc. (NASDAQ: ARQL) rose 3.8 percent to $4.70 in pre-market trading after gaining 4.86 percent on Thursday. Babcock & Wilcox Enterprises, Inc. (NYSE: BW) shares rose 2.9 percent to $2.85 in pre-market trading after climbing 7.78 percent on Thursday. Bilibili Inc. (NASDAQ: BILI) shares rose 2.5 percent to $14.20 in pre-market trading after surging 11.33 percent on Thursday.

  Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

• [By Logan Wallace]

  BidaskClub upgraded shares of ArQule (NASDAQ:ARQL) from a hold rating to a buy rating in a report released on Saturday.

  A number of other research firms have also issued reports on ARQL. Roth Capital upped their price target on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a research report on Wednesday, April 4th. ValuEngine upgraded ArQule from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, B. Riley set a $4.00 price target on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $4.69.

• [By Stephan Byrd]

  ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

• [By Maxx Chatsko]

  Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning.�

• [By Ethan Ryder]

  Get a free copy of the Zacks research report on ArQule (ARQL)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Biotech Stocks To Watch For 2018: Biogen Idec Inc(BIIB)

Advisors' Opinion:

• [By Lisa Levin] Companies Reporting Before The Bell United Technologies Corporation (NYSE: UTX) is estimated to report quarterly earnings at $1.51 per share on revenue of $14.62 billion. The Coca-Cola Company (NYSE: KO) is expected to report quarterly earnings at $0.46 per share on revenue of $7.31 billion. Caterpillar Inc. (NYSE: CAT) is projected to report quarterly earnings at $2.07 per share on revenue of $11.93 billion. Verizon Communications Inc. (NYSE: VZ) is expected to report quarterly earnings at $1.11 per share on revenue of $31.22 billion. Lockheed Martin Corporation (NYSE: LMT) is estimated to report quarterly earnings at $3.42 per share on revenue of $11.28 billion. The Sherwin-Williams Company (NYSE: SHW) is projected to report quarterly earnings at $3.15 per share on revenue of $3.94 billion. Biogen Inc. (NASDAQ: BIIB) is expected to report quarterly earnings at $5.92 per share on revenue of $3.15 billion. 3M Company (NYSE: MMM) is estimated to report quarterly earnings at $2.52 per share on revenue of $8.26 billion. JetBlue Airways Corporation (NASDAQ: JBLU) is projected to report quarterly earnings at $0.2 per share on revenue of $1.75 billion. Eli Lilly and Company (NYSE: LLY) is expected to report quarterly earnings at $1.13 per share on revenue of $5.49 billion. Harley-Davidson, Inc. (NYSE: HOG) is estimated to report quarterly earnings at $0.88 per share on revenue of $1.25 billion. Corning Incorporated (NYSE: GLW) is expected to report quarterly earnings at $0.3 per share on revenue of $2.50 billion. Centene Corporation (NYSE: CNC) is projected to report quarterly earnings at $1.88 per share on revenue of $13.28 billion. The Travelers Companies, Inc. (NYSE: TRV) is estimated to report quarterly earnings at $2.77 per share on revenue of $6.75 billion. Wipro Limited (NYSE: WIT) is expected to report quarterly earnings at $0.07 per share on revenue of $2.16 billion. PACCAR Inc (NASDAQ: PCAR) is projected to
• [By Logan Wallace]

  Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Tuesday, April 24th. The biotechnology company reported $6.05 earnings per share for the quarter, topping the consensus estimate of $5.93 by $0.12. The firm had revenue of $3.13 billion for the quarter, compared to analyst estimates of $3.15 billion. Biogen had a net margin of 23.54% and a return on equity of 37.64%. Biogen’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.20 earnings per share. research analysts anticipate that Biogen will post 23.94 earnings per share for the current year.

• [By Chris Lange]

  Short interest in Biogen Inc. (NASDAQ: BIIB) decreased to 3.45 million shares from the previous 3.50 million. The stock recently traded at $274.50, within a 52-week range of $244.28 to $370.57.

Best Biotech Stocks To Watch For 2018: Amgen Inc.(AMGN)

Advisors' Opinion:

• [By Zacks]

  The FDA also approved biosimilar Erelzi in 2016. However, the launch is pending in the United States due to an ongoing litigation with Amgen (NASDAQ: AMGN).

• [By Cory Renauer]

  There's a lot for investors to like about�Amgen Inc. (NASDAQ:AMGN) and�Biogen Inc. (NASDAQ:BIIB). Both of these biotech stocks have produced tremendous returns over the past couple of decades, and the businesses they represent still generate enormous profits.�

• [By ]

  Celgene (CELG) : "I'd rather buy Amgen (AMGN) or Regeneron Pharmaceuticals (REGN) . I think Celgene overpaid for that acquisition a few years ago."

• [By Logan Wallace]

  Shares of Amgen (NASDAQ:AMGN) have earned an average recommendation of “Hold” from the twenty-seven research firms that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and ten have given a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $193.19.

• [By Chris Lange]

  And Amgen Inc. (NASDAQ: AMGN) will report its most recent quarterly results late Thursday. The consensus forecast is $3.24 in EPS and $5.43 billion in revenue. Shares closed on Friday at $171.56, in a 52-week range of $152.16 to $201.23. The consensus price target is $195.14.

Top Low Price Stocks To Own For 2019

tags:WEC,CVI,AXSM,

In my very first MannKind article I offered for my SA readers, I made the following statement:

Wall Street gurus are always smarter than the retail investor that doesn't do their homework.

I have mentioned several times that MannKind's (NASDAQ:MNKD) management understands the reality and has done a remarkable job in keeping the company hooked up to a life support system that has allowed them to be one of the few (other than the short-sellers) to benefit from these four years of futility for the retail investors. In recent days, with the flurry of superfluous SEC filings and press releases this has only resulted in the stock falling to a near all-time low price. The time is neigh for this saga becoming history so we can close the books on this financial fiasco. It's now clear who has done their homework on MannKind!

Top Low Price Stocks To Own For 2019: WEC Energy Group, Inc.(WEC)

Advisors' Opinion:

• [By Shane Hupp]

  Get a free copy of the Zacks research report on WEC Energy Group (WEC)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Joseph Griffin]

  Get a free copy of the Zacks research report on WEC Energy Group (WEC)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top Low Price Stocks To Own For 2019: CVR Energy Inc.(CVI)

Advisors' Opinion:

• [By Stephan Byrd]

  CVR Energy Inc. (NYSE:CVI) shares hit a new 52-week high and low during mid-day trading on Monday . The stock traded as low as $39.74 and last traded at $39.69, with a volume of 566335 shares traded. The stock had previously closed at $36.81.

• [By Stephan Byrd]

  CVR Energy Inc. (NYSE:CVI) reached a new 52-week high and low during trading on Wednesday . The stock traded as low as $41.88 and last traded at $41.81, with a volume of 8024 shares trading hands. The stock had previously closed at $41.64.

Top Low Price Stocks To Own For 2019: Axsome Therapeutics, Inc.(AXSM)

Advisors' Opinion:

• [By Max Byerly]

  Axsome Therapeutics (NASDAQ:AXSM) released its quarterly earnings results on Tuesday. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.09, Bloomberg Earnings reports.

• [By Lisa Levin] Gainers Genprex, Inc. (NASDAQ: GNPX) shares gained 86.76 percent to close at $11.00 on Thursday. Comstock Resources, Inc. (NYSE: CRK) shares climbed 47.06 percent to close at $7.00 after the company disclosed a deal with Arkoma Drilling L.P. and Williston Drilling, L.P. to buy oil & gas properties in North Dakota. Comstock announced withdrawal of tender offers for outstanding secured notes. Ceridian HCM Holding Inc. (NASDAQ: CDAY) gained 41.86 percent to close at $31.21. MarineMax, Inc. (NYSE: HZO) shares rose 26.5 percent to close at $22.20 as the company posted upbeat Q2 results and raised its FY18 outlook. Concord Medical Services Holdings Limited (NYSE: CCM) jumped 24.92 percent to close at $4.06. Mattersight Corporation (NASDAQ: MATR) shares climbed 23.26 percent to close at $2.65 after the company agreed to be purchased by NICE Ltd. Chipotle Mexican Grill, Inc. (NYSE: CMG) rose 24.44 percent to close at $422.50 as the company reported stronger-than-expected results for its first quarter on Wednesday. Ultra Clean Holdings, Inc. (NASDAQ: UCTT) gained 17.75 percent to close at $18.64 following upbeat Q1 earnings. PCM, Inc. (NASDAQ: PCMI) rose 16.59 percent to close at $12.30 following Q1 results. Zymeworks Inc. (NASDAQ: ZYME) rose 16.06 percent to close at $15.25. Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) shares climbed 14.5 percent to close at $121.42 as the company posted reported Q1 beat And raised FY18 outlook. Advanced Micro Devices, Inc. (NASDAQ: AMD) shares gained 13.7 percent to close at $11.04 as the company reported upbeat results for its first quarter. Axsome Therapeutics, Inc. (NASDAQ: AXSM) rose 13.21 percent to close at $3.00 after the company disclosed a positive outcome of the interim analysis of STRIDE-1 Phase 3 trial of AXS-05 in treatment resistant depression. O'Reilly Automotive, Inc. (NASDAQ: ORLY) jumped 13.06 percent to close at $257.40 following upbeat Q1 profit. BioTelemetry,
• [By Paul Ausick]

  Axsome Therapeutics Inc. (NASDAQ: AXSM) traded down about 43% Tuesday and posted a new 52-week low of $3.20 after closing Monday at $5.55. The 52-week high is $6.45. Volume was about 3.8 million, about 19 times the daily average of around 220,000 shares. The company will stop a “futile” portion of a trial of its treatment for knee osteoarthritis.

• [By Lisa Levin] Gainers Axsome Therapeutics, Inc. (NASDAQ: AXSM) rose 22.6 percent to $3.25 in pre-market trading after the company disclosed a positive outcome of the interim analysis of STRIDE-1 Phase 3 trial of AXS-05 in treatment resistant depression. Mattersight Corporation (NASDAQ: MATR) shares rose 23.2 percent to $2.65 in pre-market trading after the company agreed to be purchased by NICE Ltd. Comstock Resources, Inc. (NYSE: CRK) rose 21.2 percent to $5.77 in pre-market trading after the company disclosed a deal to buy oil & gas properties in North Dakota from Arkoma, Williston Drilling for about $620 million. The company also announced withdrawal of tender offers for outstanding secured notes. Chipotle Mexican Grill, Inc. (NYSE: CMG) rose 13.7 percent to $386.00 in pre-market trading as the company reported stronger-than-expected results for its first quarter on Wednesday. Quantenna Communications, Inc. (NASDAQ: QTNA) shares rose 12.6 percent to $14.70 in pre-market trading. Quantenna is expected to release Q1 results on April 30.. BioTelemetry, Inc. (NASDAQ: BEAT) rose 11.1 percent to $37.50 in pre-market trading as the company reported stronger-than-expected earnings for its first quarter. Penn National Gaming, Inc. (NASDAQ: PENN) rose 10.4 percent to $29.00 in pre-market trading after reporting strong Q1 results. O'Reilly Automotive, Inc. (NASDAQ: ORLY) rose 9.8 percent to $250.00 in pre-market trading following upbeat Q1 profit. Advanced Micro Devices, Inc. (NASDAQ: AMD) shares rose 9.4 percent to $10.62 in pre-market trading as the company reported upbeat results for its first quarter. CYS Investments, Inc. (NYSE: CYS) rose 9.1 percent to $7.22 in pre-market trading after the company agreed to be acquired by Two Harbors Investment Corp (NYSE: TWO). GNC Holdings, Inc. (NYSE: GNC) rose 8.3 percent to $4.18 in pre-market trading after reporting Q1 results. Domino's Pizza, Inc. (NYSE: DPZ) shares rose 7.6 percent to $251.2
• [By Lisa Levin] Gainers Comstock Resources, Inc. (NYSE: CRK) shares shot up 52 percent to $7.235 after the company disclosed a deal with Arkoma Drilling L.P. and Williston Drilling, L.P. to buy oil & gas properties in North Dakota. Comstock announced withdrawal of tender offers for outstanding secured notes. MarineMax, Inc. (NYSE: HZO) shares gained 24.2 percent to $21.80 as the company posted upbeat Q2 results and raised its FY18 outlook. Mattersight Corporation (NASDAQ: MATR) shares rose 22 percent to $2.625 after the company agreed to be purchased by NICE Ltd. Chipotle Mexican Grill, Inc. (NYSE: CMG) jumped 21.3 percent to $411.871 as the company reported stronger-than-expected results for its first quarter on Wednesday. Axsome Therapeutics, Inc. (NASDAQ: AXSM) rose 17 percent to $3.10 after the company disclosed a positive outcome of the interim analysis of STRIDE-1 Phase 3 trial of AXS-05 in treatment resistant depression. Ultra Clean Holdings, Inc. (NASDAQ: UCTT) rose 15.9 percent to $18.34 following upbeat Q1 earnings. PCM, Inc. (NASDAQ: PCMI) gained 15.6 percent to $12.20 following Q1 results. O'Reilly Automotive, Inc. (NASDAQ: ORLY) surged 14.4 percent to $260.3901 following upbeat Q1 profit. Concord Medical Services Holdings Limited (NYSE: CCM) gained 13.8 percent to $3.70. Penn National Gaming, Inc. (NASDAQ: PENN) rose 13.5 percent to $29.815 after reporting strong Q1 results. BioTelemetry, Inc. (NASDAQ: BEAT) rose 13.5 percent to $38.30 as the company reported stronger-than-expected earnings for its first quarter. Advanced Micro Devices, Inc. (NASDAQ: AMD) shares rose 13.1 percent to $10.985 as the company reported upbeat results for its first quarter. SJW Group (NYSE: SJW) shares gained 11.8 percent to $63.59 following Q1 results. California Water Service Group made an offer for SJW. Churchill Downs Incorporated (NASDAQ: CHDN) climbed 9.8 percent to $278.40 following Q1 results. CYS Investments, Inc. (NYSE: CYS)

Buy or sell: Top stock trading ideas by Vinay Rajani, Prakash Gaba & Rajesh Agarwal

The index slipped for a fifth consecutive session in a row. It broke below its crucial support placed at 50-DEMA, and 100-DMA placed at 10,557, and 10,538�respectively.

Bears have tightened their hold on D-Street which is evident from the fact that the widely tracked Supertrend indicator gave a sell signal on the charts today.�MACD gave a sell signal on daily charts last week.

The Nifty which opened at 10,616 rose to an intraday high of 10,621 but then bulls took control and pushed the index below 10600 levels. The index slipped to�an intraday low of 10,505 before closing 79 points lower at 10,516.

India VIX moved up by 1.84 percent at 14.41 levels. On the options front, maximum Put OI is placed at 10,500 followed by 10,600 strikes while maximum Call�OI is placed at 11,000 followed by 10,800 strikes.

related news Time to sell Nifty in range of 10,500-10,600; next target placed at 10,325 Markets@Moneycontrol: Nifty likely to open flat; 3 stocks which you can go short on Buy Mahindra & Mahindra Financial Services: Akash Jain

According to Pivot charts, the key support level is placed at 10,474.43, followed by 10,432.17. If the index starts moving upwards, key resistance levels to�watch out are 10,590.33 and 10,663.97.

The Nifty Bank index closed at 25,750.8 on Monday. The important Pivot level, which will act as crucial support for the index, is placed at 25,601.8, followed by 25,452.8. On the upside, key resistance levels are placed at 25,983.3, followed by 26,215.8.

Vinay Rajani of HDFC Securities

Sell Wipro with target at Rs 245 and stop loss at Rs 280

Sell Apollo Hospitals with target at Rs 890 and stop loss at Rs 1,050

Sell Bharti Airtel with target at Rs335 and stop loss at Rs 380

Prakash Gaba of prakashgaba.com

Sell BEML with target at Rs 900 and stop loss at Rs 980

Sell Delta Corp with target of Rs 220 and stop loss at Rs 240

Rajesh Agarwal of AUM Capital

Buy Bharat Petroleum Corporation with stop loss at Rs 380 and target at Rs 410

Buy AU Small Finance Bank with stop loss at Rs 690 and target at Rs 723

Buy Infosys with stop loss at Rs 1162 and target at Rs 1206

Buy West Coast Paper Mills with stop loss at Rs 280 and target at Rs 296

Sell KPIT Technologies with stop loss at Rs 259 and target at Rs 245

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Chevron Co. (CVX) Holdings Trimmed by Beddow Capital Management Inc.

Beddow Capital Management Inc. lessened its holdings in Chevron Co. (NYSE:CVX) by 14.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 13,173 shares of the oil and gas company’s stock after selling 2,312 shares during the quarter. Beddow Capital Management Inc.’s holdings in Chevron were worth $1,649,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Standard Life Aberdeen plc boosted its holdings in Chevron by 4.6% in the fourth quarter. Standard Life Aberdeen plc now owns 3,849,359 shares of the oil and gas company’s stock worth $482,335,000 after acquiring an additional 170,953 shares in the last quarter. Mutual Advisors LLC purchased a new position in shares of Chevron in the fourth quarter worth about $2,052,000. Brown Advisory Securities LLC raised its stake in shares of Chevron by 3.5% in the fourth quarter. Brown Advisory Securities LLC now owns 23,116 shares of the oil and gas company’s stock worth $2,898,000 after purchasing an additional 782 shares during the last quarter. State of Tennessee Treasury Department raised its stake in shares of Chevron by 4.2% in the fourth quarter. State of Tennessee Treasury Department now owns 904,014 shares of the oil and gas company’s stock worth $113,173,000 after purchasing an additional 36,095 shares during the last quarter. Finally, First Republic Investment Management Inc. raised its stake in shares of Chevron by 4.5% in the fourth quarter. First Republic Investment Management Inc. now owns 1,678,438 shares of the oil and gas company’s stock worth $210,123,000 after purchasing an additional 71,894 shares during the last quarter. 64.99% of the stock is owned by institutional investors and hedge funds.

Get Chevron alerts:

Several research analysts have recently issued reports on CVX shares. Goldman Sachs cut Chevron from a “conviction-buy” rating to a “buy” rating in a research note on Monday, February 5th. Barclays raised their price objective on Chevron from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Monday, April 30th. Credit Suisse Group reduced their price objective on Chevron from $129.00 to $123.00 and set a “neutral” rating for the company in a research note on Wednesday, March 7th. Vetr upgraded Chevron from a “hold” rating to a “buy” rating and set a $117.38 price objective for the company in a research note on Tuesday, April 3rd. Finally, ValuEngine upgraded Chevron from a “hold” rating to a “buy” rating in a research note on Wednesday, April 18th. One analyst has rated the stock with a sell rating, seven have given a hold rating and nineteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $131.92.

In other news, EVP Pierre R. Breber sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, May 14th. The stock was sold at an average price of $130.41, for a total value of $3,260,250.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Patricia E. Yarrington sold 135,000 shares of the business’s stock in a transaction that occurred on Friday, May 11th. The shares were sold at an average price of $130.00, for a total value of $17,550,000.00. Following the completion of the sale, the chief financial officer now owns 139,838 shares of the company’s stock, valued at $18,178,940. The disclosure for this sale can be found here. Insiders sold 377,000 shares of company stock valued at $48,519,200 over the last 90 days. Company insiders own 0.38% of the company’s stock.

Shares of Chevron opened at $127.86 on Friday, Marketbeat.com reports. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.04 and a quick ratio of 0.84. The company has a market cap of $247.30 billion, a P/E ratio of 34.56, a P/E/G ratio of 2.49 and a beta of 1.14. Chevron Co. has a twelve month low of $102.55 and a twelve month high of $133.88.

Chevron (NYSE:CVX) last posted its quarterly earnings data on Friday, April 27th. The oil and gas company reported $1.90 EPS for the quarter, beating the Zacks’ consensus estimate of $1.45 by $0.45. The business had revenue of $37.76 billion during the quarter, compared to analysts’ expectations of $40.34 billion. Chevron had a return on equity of 5.83% and a net margin of 6.95%. The business’s revenue was up 13.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.23 earnings per share. equities analysts predict that Chevron Co. will post 7.44 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 11th. Stockholders of record on Friday, May 18th will be given a $1.12 dividend. This represents a $4.48 dividend on an annualized basis and a dividend yield of 3.50%. The ex-dividend date of this dividend is Thursday, May 17th. Chevron’s dividend payout ratio (DPR) is presently 121.08%.

About Chevron

Chevron Corporation, through its subsidiaries, engages in integrated energy, chemicals, and petroleum operations worldwide. The company operates in two segments, Upstream and Downstream. The Upstream segment is involved in the exploration, development, and production of crude oil and natural gas; processing, liquefaction, transportation, and regasification associated with liquefied natural gas; transportation of crude oil through pipelines; and transportation, storage, and marketing of natural gas, as well as operates a gas-to-liquids plant.

Swiss National Bank Has $28.20 Million Holdings in Imperial Oil (IMO)

Swiss National Bank cut its position in shares of Imperial Oil (NYSEAMERICAN:IMO) (TSE:IMO) by 6.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,066,300 shares of the energy company’s stock after selling 76,100 shares during the period. Swiss National Bank owned approximately 0.13% of Imperial Oil worth $28,203,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of IMO. Virginia Retirement Systems ET AL raised its stake in shares of Imperial Oil by 91.2% in the 1st quarter. Virginia Retirement Systems ET AL now owns 135,700 shares of the energy company’s stock valued at $3,591,000 after acquiring an additional 64,709 shares during the period. Raymond James & Associates raised its stake in shares of Imperial Oil by 41.9% in the 4th quarter. Raymond James & Associates now owns 12,533 shares of the energy company’s stock valued at $391,000 after acquiring an additional 3,700 shares during the period. Luminus Management LLC purchased a new stake in shares of Imperial Oil in the 4th quarter valued at approximately $6,238,000. Two Sigma Investments LP purchased a new stake in shares of Imperial Oil in the 4th quarter valued at approximately $959,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of Imperial Oil by 2.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 263,342 shares of the energy company’s stock valued at $8,214,000 after acquiring an additional 6,417 shares during the period.

Get Imperial Oil alerts:

NYSEAMERICAN IMO opened at $32.70 on Friday. Imperial Oil has a 52 week low of $25.91 and a 52 week high of $33.11.

Imperial Oil (NYSEAMERICAN:IMO) (TSE:IMO) last posted its quarterly earnings results on Friday, April 27th. The energy company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.38 by $0.11. Imperial Oil had a negative net margin of 1.70% and a negative return on equity of 2.22%. The company had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $8.65 billion. During the same quarter in the previous year, the business posted $0.39 EPS. The firm’s revenue was up 10.9% on a year-over-year basis.

The company also recently declared a quarterly dividend, which will be paid on Sunday, July 1st. Shareholders of record on Friday, June 1st will be issued a dividend of $0.1479 per share. This represents a $0.59 annualized dividend and a yield of 1.81%. The ex-dividend date is Thursday, May 31st. This is a boost from Imperial Oil’s previous quarterly dividend of $0.13.

Several equities research analysts recently weighed in on the stock. Bank of America assumed coverage on shares of Imperial Oil in a research note on Thursday, April 5th. They set an “underperform” rating on the stock. TheStreet downgraded shares of Imperial Oil from a “b-” rating to a “c” rating in a research note on Friday, February 2nd. Raymond James downgraded shares of Imperial Oil from a “market perform” rating to an “underperform” rating in a research note on Tuesday, April 24th. Morgan Stanley cut their target price on shares of Imperial Oil from $42.00 to $40.00 and set an “underweight” rating on the stock in a research note on Wednesday, January 24th. Finally, Royal Bank of Canada raised shares of Imperial Oil from an “underperform” rating to a “sector perform” rating in a research note on Wednesday, January 31st. Five analysts have rated the stock with a sell rating and ten have issued a hold rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $41.60.

Imperial Oil Profile

Imperial Oil Limited explores for, produces, and sells crude oil and natural gas in Canada. The company operates through three segments: Upstream, Downstream, and Chemical. The Upstream segment explores for and produces crude oil, natural gas, synthetic oil, and bitumen. As of December 31, 2017, this segment had 450 million oil-equivalent barrels of proved undeveloped reserves.

Want to see what other hedge funds are holding IMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Imperial Oil (NYSEAMERICAN:IMO) (TSE:IMO).